

Science of COVID-19

Laurence Smart
3-4-2022
(www.CanberraForerunners.org)



**Use the Epoch Times phone app
to read articles and watch
videos without subscribing**

nature

NEWS FEATURE | 29 January 2021

COVID-19 rarely spreads through surfaces. So why are we still deep cleaning?

THE EXPOSÉ

US Military Documents: Ivermectin “Works Throughout All Phases of Illness”

BY RHODA WILSON ON JANUARY 16, 2022 • (3 COMMENTS)



Nurse Ellen Quinones prepares a dose of Moderna's COVID-19 vaccine at the Bathgate Post Office vaccination facility in the Bronx, N.Y., on Jan. 10, 2021. (Kevin Hagen/Pool via Reuters)

PREMIUM **VACCINES & SAFETY**

British Medical Journal Demands Immediate Release of All COVID-19 Vaccine, Treatment Data

By [Katabella Roberts](#) | January 21, 2022 Updated: January 21, 2022



ABS data reveals over 90 per cent of COVID-19 deaths had other health conditions

New data released by the Australian Bureau of Statistics has found that more than 90 per cent of those who died from COVID-19 had other health conditions.



Jack Mahony Digital Reporter



2 min read

February 17, 2022 - 6:40PM

sky news .COM.AU



55 comments



PODCAST



CONSERVATIVE ONE

DEFENDING TRADITIONS AND FREEDOM



WITH GEORGE CHRISTENSEN,
AUSTRALIAN MEMBER OF PARLIAMENT

20 Jan, 2022

THE "VACCINES" ARE EXPERIMENTAL THERAPIES — WITH PROF. NIKOLAI PETROVSKY



The "Vaccines" Are Experimental Therapies — with Prof. Nikolai Petrovsky
CONSERVATIVE ONE: PANDEMIC UNMASKED (HOSTED BY GEORGE CHRISTENSEN MP)



www.georgechristensen.com.au/podcast/petrovsky

[31:30]

I-RECOVER

1/4

Management Protocol for Long Haul COVID-19 Syndrome (LHCS)

The approach outlined below is a consensus protocol based on a collaboration led by Dr. Mobeen Syed (“Dr. Been”), Dr. Tina Peers, and the FLCCC Alliance. Given the lack of clinical treatment trials of Long Haul COVID-19 Syndrome, these recommendations are based on the pathophysiologic mechanisms of COVID-19 and post-viral illnesses along with our collective experience observing profound and sustained clinical responses achieved with the treatment approaches below.

This protocol has also been used to treat **post-vaccine inflammatory syndromes** with similar success. As with all FLCCC Alliance protocols, the components, doses, and durations will evolve as more clinical data accumulates.

If the patient presents with shortness of breath or low oxygen levels: Refer to lung specialist if available, otherwise perform chest imaging (CT preferred) to assess for secondary organizing Pneumonia (OP). If findings consistent with secondary OP found, initiate Corticosteroid Therapy as below. May need to repeat or prolong course of treatment if symptoms or oxygen needs persist.

1. FIRST LINE THERAPIES

- **IVERMECTIN:** 0.2 mg/kg body weight. Once daily for 1 week.¹
- **PREDNISONE:** 10–15 mg daily for 3 weeks. Taper to 10 mg for three days, then 5 mg for three days and then stop.²
- Low dose **NALTREXONE** (LDN): Begin with 1 mg daily and increase to 4.5 mg as required. May take 2–3 months for full effect.
- **OMEGA-3 FATTY ACIDS:** Vascepa, Lovaza or DHA/EPA 4 g per day. Omega-3 fatty acids play an important role in the

2. SECOND LINE THERAPIES

- **FLUVOXAMINE** (low dose): 25 mg once daily. Stop if the symptoms increase. Caution with the use of other anti-depressants and psychiatric drugs. Taper and discontinue once symptoms improve.
- **ATORVASTATIN:** 20–40 mg once daily. Caution in patients with Postural Orthostatic Tachycardia Syndrome (POTS); may exacerbate symptoms.





A health care worker fills a syringe with Pfizer's COVID-19 vaccine in a file image. (Robyn Beck/AFP via Getty Images)

Heart Issues Detected Months After COVID-19 Vaccination: Study

By [Zachary Stieber](#) | March 27, 2022 Updated: March 28, 2022






Safeway pharmacist Ashley McGee fills a syringe with the Pfizer COVID-19 vaccination in California on Oct. 1, 2021. (Justin Sullivan/Getty Images)

Newly Released Pfizer Documents Reveal COVID Jab Dangers

By [Joseph Mercola](#) | March 22, 2022 Updated: March 24, 2022



This is a teaching document for educational purposes



L.D. Smart

COPYRIGHT

*This document is **free** to copy, republish and distribute, but only 'as is'.*

All quotes are copyrighted to the authors credited.

Free graphics are from www.clker.com & free photos are from commons.wikimedia.org.

*All Canberra Forerunner documents are licensed under
[Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License](https://creativecommons.org/licenses/by-nc-nd/3.0/)*